All the latest News From Myanmar

USSOCOM Awards Vricon Foreign Comparative Test Contract

Vricon to increase the resolution and accuracy of SOCOM’s 3D geospatial data McLean, Virginia, Nov. 09, 2017 (GLOBE NEWSWIRE) — The US Special Operations Command (USSOCOM) awarded Vricon a contract for a Foreign Comparative Test for commercial data, software, and testing to increase the resolution and accuracy of the Command’s 3D geospatial data.  Vricon also will work to automate workflows […]

Nasdaq Wins RiskTech100® Best Operational Risk & GRC Category

Awarded by Chartis Research, the accolade spotlights the major players in risk technology  NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) — Nasdaq, Inc. (Nasdaq:NDAQ), one of the world’s leading Governance, Risk management and Compliance (GRC) solution providers, has won the Best Operational Risk & GRC provider at the RiskTech100® 2018 awards. Nasdaq’s four commercial offerings were considered […]

Disruptive Semiconductor Technology Leader Luxcore Signs Multi-year Colocation Deal with INAP

Luxcore selects INAP to support their ground breaking second generation LambdaRouterTM — the first full wavelength optical router. INAP chosen for its global presence in strategic markets, carrier neutrality and signature Performance IPTM service. ATLANTA, Nov. 09, 2017 (GLOBE NEWSWIRE) — Internap Corporation (NASDAQ:INAP), (“INAP” or the “Company”), a provider of high-performance internet infrastructure including […]

Posted in Uncategorized

RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease

Top-line results are expected to be announced in mid-2018 The Phase III study evaluating RHB-104 for Crohn’s disease (MAP US study) is a randomized, double-blind, placebo-controlled study that is evaluating the safety and efficacy of RHB-104 in 331 subjects with moderately to severely active Crohn’s disease Worldwide sales of Crohn’s disease therapies exceeded $7.6 billion […]

Posted in Uncategorized

RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease

Top-line results are expected to be announced in mid-2018 The Phase III study evaluating RHB-104 for Crohn’s disease (MAP US study) is a randomized, double-blind, placebo-controlled study that is evaluating the safety and efficacy of RHB-104 in 331 subjects with moderately to severely active Crohn’s disease Worldwide sales of Crohn’s disease therapies exceeded $7.6 billion […]

Posted in Uncategorized

VistaJet Customers Grow by 50% in the Middle East as the Company Expands Its Reach

The leader in global business aviation increases its offering to continue positive momentum in the region New Program hours doubled year over year New Program customers rose by 50% year over year Full flying service now available in and out of Saudi Arabia as expansion continues Results follow $150 million investment from Rhône Capital     DUBAI, […]

Posted in Uncategorized

Telix Pharmaceuticals Limited Successfully Completes $50 Million Oversubscribed Initial Public Offering

MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has successfully raised $50 million following the close of its fully underwritten Initial Public Offering (IPO). The IPO was strongly […]

Posted in Uncategorized